Mosquito-borne diseases, such as dengue and malaria, pose significant global health burdens. Unfortunately, current control methods based on insecticides and environmental maintenance have fallen short of eliminating the disease burden. Scalable, deployable, genetic-based solutions are sought to reduce the transmission risk of these diseases. Pathogen-blocking Wolbachia bacteria, or genome engineering-based mosquito control strategies including gene drives have been developed to address these problems, both requiring the release of modified mosquitoes into the environment. Here, we review the latest developments, notable similarities, and critical distinctions between these promising technologies and discuss their future applications for mosquito-borne disease control.
Roughly half of the world’s population is at risk of mosquito-borne diseases, with the highest-burden for socioeconomically disadvantaged populations. Urbanization, globalization, climate change, and land-use shifts have each contributed to the re-emergence and expansion of mosquito-borne diseases. For example, dengue incidence has increased >30-fold in the past 50 years and outbreaks of chikungunya, yellow fever, and malaria have increased in size and frequency since 2014. The 2015–2016 Zika virus (ZIKV) epidemic in Latin America and the Caribbean also resulted in hundreds of thousands of infections, resulting in large-scale socioeconomic disruptions. Supply-chain disruptions due to the coronavirus disease 2019 pandemic are expected to increase the number of malaria-related deaths in sub-Saharan Africa in 2020–2021 as well.
There is a critical need for safe, sustainable approaches to reduce the burden of mosquito-borne pathogens. Common mosquito control strategies with chemical insecticides and environmental management are only moderately effective, in part due to resistance arising from physiological (e.g., insecticide resistance) and behavioral changes (e.g., mosquitoes change their blood-feeding times in response to bed nets). Chemical interventions also have unintended effects on non-target insects, including pollinators.
Recently there has been an expansion in the development of genetic control technologies, involving modified mosquitoes designed with the goal to achieve either population suppression (Fig. 1A), or population modification (Fig. 1B). Suppression strategies include the sterile insect technique (SIT), incompatible insect technique (IIT), and various transgene-based technologies including gene drives. In population modification strategies, pathogen-resistant (“refractory”) mosquitoes are designed to be released into wild populations, where they can spread their heritable modifications to prevent pathogen transmission. Examples include the use of the heritable pathogen-blocking Wolbachia (Box 1) and various transgenic technologies. In this review, we compare and contrast mosquito control interventions aimed at either population suppression, or modification, highlighting recent developments in the use of Wolbachia-infected mosquitoes and transgenic strategies.
Wolbachia-based approaches for mosquito control
Wolbachia is an intracellular reproductive parasite of arthropods and nematodes, naturally found in many insect species. Transmitted vertically from mother to offspring, Wolbachia maximize their transmission by manipulating host reproduction through feminization, parthenogenesis, male-killing, cytoplasmic incompatibility (CI), and by increasing host fitness with or without reproductive manipulation1. Through CI, Wolbachia-infected females produce viable Wolbachia-infected offspring when mated with uninfected males, or males infected with the same Wolbachia strain. However, Wolbachia-infected males only produce viable offspring when mated with females infected with the same Wolbachia strain (see figure in Box 1). Thus, although males are essentially dead ends for Wolbachia transmission, they can reduce the reproductive output of uninfected females, giving Wolbachia-infected females a relative reproductive advantage and enabling spread into populations. Interestingly, some important vector species, including Aedes aegypti, are naturally free of Wolbachia. Therefore, to use Wolbachia for control, a Wolbachia strain must be heritably introduced to establish a Wolbachia-infected colony.
Wolbachia-based population suppression
Wolbachia IIT is a population suppression approach whereby male mosquitoes infected with Wolbachia are released into a wild population lacking that Wolbachia strain. Mating between Wolbachia-infected males and wild females results in nonviable offspring. Multiple male-only releases over time can suppress/eliminate mosquito populations and potentially interrupt disease transmission (Fig. 1A). Ideal strains for Wolbachia IIT should have high penetrance of sterility in matings between Wolbachia-infected males and wild females (ideally 100%) and should ensure similar mating competitiveness between Wolbachia-infected and wild males. Several Wolbachia strains that satisfy these conditions have been successfully transfected into Aedes, Anopheles, and Culex mosquitoes.
Despite advances, several drawbacks of IIT limit its long-term sustainability. IIT requires multiple, frequent releases of large numbers of perfectly sex-sorted male mosquitoes. The effort and resources required to implement IIT on a scale needed to disrupt disease transmission may not be sustainable for many areas. Accidental, unintended releases of Wolbachia-infected females into the population can compromise IIT as the Wolbachia-infected females are fertile with both infected and uninfected males (Box 1) and therefore their offspring inherit the infection. Over time as Wolbachia spreads, Wolbachia becomes more abundant, even fixed, rendering the Wolbachia strain obsolete for IIT due to compatibility between infected females and released males. In fact, recent Wolbachia IIT trials in Singapore to suppress populations of Ae. aegypti were compromised by the rapid establishment of the Wolbachia strain in the field resulting from accidental releases of even an extremely small fraction of females (estimated that only three females were released)2. Notably, this study employed the most advanced sex sorting technologies available today3, yet still fell short of the sex sorting efficiencies necessary to avoid Wolbachia establishment in the population2. These results suggest that Wolbachia IIT technologies alone will unlikely be fruitful for long-term, sustained population suppression, particularly in smaller populations where the unintentional release of fewer Wolbachia infected mosquitoes can lead to more rapid IIT establishment in the population. If IIT strains do become established in populations, however, their pathogen blocking properties may still reduce disease transmission and therefore remain beneficial for disease control programs (see “Wolbachia-based population modification”).
To overcome the establishment of the Wolbachia IIT strain, the Singapore trial also used a combined IIT and low-dose radiation sterilization approach to achieve sustained population suppression2. This combined IIT-SIT approach was also previously implemented in a small field trial with Aedes albopictus (Fig. 1A)4 and ensures that unintentionally released Wolbachia-infected females are sterile, preventing maternal transmission of Wolbachia to their offspring and maintaining the fidelity of the strain. While this radiation-based sterilization process can compromise fitness, it has been used for many years in SIT programs, whereby radiation is used to generate sterile offspring through the generation of chromosomal damage or lethal mutations. Notwithstanding, there remain critical questions as to whether this approach is ideal due to the impacts of radiation on fitness and possibly vector competence5. Post irradiation vector competence was not addressed in either study, but radiation treatment could increase the vector competence of released females by impacting the density or transmission of Wolbachia, or by inducing mutations in the Wolbachia itself, which could possibly affect its pathogen blocking capabilities or other natural immune functions in the vector5. When mosquito populations are already infected with another strain of Wolbachia, which is the case for Ae. albopictus, for example, it is likely unnecessary to couple IIT and SIT. This is due to bidirectional CI, whereby both directions of a cross are incompatible (Box 1), which can successfully suppress populations while retaining high male fitness and low vector competence5. The long-term sustainability of this combined IIT and SIT approach is further convoluted by the lack of data on post-intervention population recovery. Certainly, combining the two approaches will also increase the costs associated with implementing these technologies. In particular, the reduced fitness of the released Wolbachia-infected irradiated males2 may increase the quantity and frequency of releases needed to achieve significant population suppression. These considerations, along with more long-term and larger-scale data, are critical to evaluating the sustainability and scalability of these combined approaches for effective disease control.
Wolbachia-based population modification
Population modification approaches to disease control aim to modify vector populations to harbor heritable factors that reduce or block pathogen transmission. Remarkably, Wolbachia has been demonstrated to naturally reduce transmission of multiple arboviruses (i.e., dengue, West Nile, chikungunya, Zika, and Mayaro) and even the malaria parasite, Plasmodium6,7,8. Studies have suggested that Wolbachia may block pathogens by competing for fatty acids, regulating host microRNAs, or upregulating innate immune response pathways9, or may interact directly with viral RNA to limit pathogen infection, dissemination, and transmission10. The precise mechanism for the anti-pathogen transmission activity of Wolbachia remains unclear but is hypothesized to be due to either Wolbachia-associated activation of host immunity or competition between the virus and Wolbachia for cellular resources11. Both of these mechanisms could interfere with virus replication, but these interactions are complicated, varying by the host, Wolbachia strain, and pathogen.
Field trials of Wolbachia-based population modification in Australia demonstrated that Wolbachia infection rates reached up to 90% at 11 weeks following an initial release of Wolbachia-infected female mosquitoes12 and successfully reduced the dengue transmission in Cairns and Townsville cities13. High Wolbachia-infection rates were sustained for 6 months following release in dengue virus (DENV)-endemic Yogyakarta, Indonesia, where Wolbachia-infected adults or eggs were released over 20 or 24 weeks, respectively14 and, importantly, resulted in a significant reduction in dengue incidence in the treatment area15,16. High Wolbachia-infection rates (>80%) were also sustained for more than 2 years after release in DENV-endemic Kuala Lumpur, Malaysia17,18 and recently in Brazil, where significant reductions in dengue, Zika, and chikungunya incidence were also observed in Wolbachia intervention areas19. In general, Wolbachia-based population modification strategies appear to require fewer releases than IIT strategies and allow the release of both sexes of Wolbachia-infected mosquitoes, enabling long-term persistence in the environment (Fig. 1B). While these efforts are exciting, how evolutionarily stable are the Wolbachia pathogen blocking characteristics? What happens when either the virus, mosquito, or Wolbachia itself evolves over time—will the pathogen blocking abilities break down—if so how will this be resolved? These are just a minority of open questions that deserve future exploration.
Transgenic approaches for mosquito control
The “selfish” biased transmission by Wolbachia has a similar outcome to that of a gene drive (GD), also “selfish”, but a genetic-based system that can spread through populations by biasing inheritance in its favor20,21 (see figure in Box 2). While varying dramatically in their mechanisms20,22, GDs can selfishly enable their spread without necessarily conferring a selective advantage to their carriers23. This aspect is important for the genetic control of mosquitoes, as mosquito-borne pathogens generally have a little adverse effect on infected mosquitoes. Thus, refractory genes, which impart resistance to pathogens, are unlikely to confer a significant fitness advantage to their carriers. Although inundative releases may be sufficient for some purposes24, refractory genes generally need to be linked to GDs for large-scale dissemination and persistence.
Scientists are developing synthetic GDs, which are often mechanistically inspired by natural GDs (e.g., Medea, homing endonucleases) but developed from scratch, allowing them to be better understood and tailored for specific pathogens/vectors. There are several GD types with different characteristics including homing-based gene drives (HGDs)25,26,27 and sex-linked meiotic drives28,29, which have been demonstrated in mosquitoes, other GD types include Medea and various under dominance systems30,31,32. In CRISPR HGDs20,33, CRISPR-associated protein 9 (Cas9) is guided by a programmable guide RNA (gRNA) to generate a double stranded break (DSB) in a precise location. This DNA break is then repaired using the cell’s homology-directed repair (HDR) machinery. When this process occurs in the germline of heterozygous individuals, wild-type alleles get converted into drive alleles, thereby enabling super-Mendelian inheritance of the drive allele.
Despite aspirations that HGDs can solve world health issues, there are safety concerns due to the predicted ability of HGDs to persist indefinitely and invade non-target populations34. To address this, scientists have proposed various types of “confinable” [or “local”] gene drives whose properties allow them to be restricted to the vicinity of the release site(s), and sometimes also to limit their temporal persistence. For example, scientists have proposed the use of homing-based gene drive (split HGD) as an alternative to autonomous HGD25,35,36,37 (see Fig. 2F). In an autonomous drive, a single unit comprising Cas9 and guide RNA (gRNA) is inserted at a target location20,33. Split drives separate the CRISPR components across two or more genetic loci, with at least one component unable to drive. Large-scale releases can allow a split HGD to reach high frequencies and persist long-term in the target population25. However, limited introductions (e.g., accidental release36 or migrants invading non-target populations) cannot reach high frequencies, because the non-driving component is limited and declines from a low initial frequency due to negative selection. In this way, split HGDs enable spatiotemporal confinement of HGD elements25 and may provide an optimal platform for a safe phased release program of a gene drive. Split HGDs have reduced spread relative to equivalent autonomous drives, especially at low prevalence; however, this issue can be substantially restored by linking several elements together if desired38. Recent advances enabled the development of a split HGD in an Aedes mosquito25,27. Li et al. examined drive dynamics of a GD element comprising a gRNA targeting a phenotypic gene, white, together with an unlinked source of germline Cas9. Researchers achieved inheritance rates of up to 94%. This proof-of-principle study paves the way for further development of linked effectors for population modification strategies or transgenes useful for population suppression in Ae. aegypti.
Several studies have demonstrated HGD suppression systems in Anopheles mosquitoes39,40,41,42,43. An HGD was designed to target female fertility genes of An. gambiae, to decrease both female reproductive output and mosquito population size39. In another example, an HGD targeting doublesex (dsx) eliminated laboratory cage populations of An. gambiae42 (Fig. 2A). This system was designed to prevent resistant-allele accumulation at the target site, which is an issue for CRISPR-based GDs, by taking advantage of the highly conserved nature of dsx. Resistance alleles are generated when non-HDR DSB repair mechanisms create germline insertions or deletions (indels) at the target site44,45. These sites can then become resistant to drive cleavage, and as these indels accumulate over time due to increased imperfect repair events and/or positive selection of the resistance allele, they will lead to extinction of the GD from the population46. To attempt to further incrrease the stability of the drive, an alternative GD design was engineered by incorporating a previously characterized X-chromosome shredding nuclease, I-PpoI, into the CRISPR-based dsx GD system43 (Fig. 2B). Experiments revealed a biased sex ratio towards males and the eventual collapse of a small laboratory cage population. These innovative studies demonstrate the versatility of new technologies to overcome previous limitations. Given that these suppression drives have not been trialed in the field to date, it’s unclear whether these systems will be stable enough to face the existing natural variation and expected evolution of resistance in the environment and persist and function long enough to suppress and eliminate a target species.
Non-GD, genetic-based technologies have demonstrated population and disease suppression in smaller-scale field trials. The release of Insects carrying a Dominant Lethal gene (RIDL) has been successfully used for many years for the control of insect pests, including mosquitoes47,48 (Fig. 2C, D; Table 1). Despite successes with RIDL, costs associated with mass-rearing using tetracycline and fitness costs associated with the initial strains have motivated researchers to innovate other non-GD technologies and RIDL strains with lower fitness costs. An alternative, non-GD approach for mosquito control, precision-guided sterile insect technique (pgSIT), takes advantage of efficient CRISPR-mediated biallelic lethal/sterile mosaicism to produce sterile males and dead/intersex females49. Initially demonstrated in fruit flies, this approach circumvents the fitness costs associated with SIT (i.e., radiation-associated costs) and RIDL (i.e., tetracycline-associated costs). The pgSIT study characterized three dual-gRNA strains, all targeting the beta-2-tubulin gene and one of three sex determination genes: sex lethal, transformer, or the female isoform of dsx. When these dual gRNA strains were crossed to three Cas9 strains, male progeny were sterile, and females were either dead or converted to sterile intersex. Importantly, pgSIT males were able to compete with wild-type males for females. This approach provides an exciting opportunity for application in mosquitoes, because genes like beta-2-tubulin, and dsx, are conserved in mosquitoes (Fig. 2E). Recently, this system was adapted to Ae. aegypti50 by leveraging U6 promoters for gRNA expression25 targeting essential genes and available Cas9 strains51. This technology works during early embryogenesis, enabling the release of eggs (rather than fragile adult mosquitoes) into the field. Given that sterile pgSIT males can be generated and scaled in a factory then released, neither naturally existing polymorphisms in the gRNA target sites, nor the evolution of resistance in the wild, are expected to impact this approach, as they would for gene drives, and therefore this technology may prove to be more evolutionarily stable and effective.
Using synthetic, or naturally occurring, effector genes to reduce pathogen transmission is an alternative approach for mosquito-borne disease control. One concern with population suppression strategies is that eradicating mosquito populations may lead to continuous reinvasion from neighboring populations, or other species that occupy the same ecological niche. Population modification approaches may provide a sustainable and cost-effective means of maintaining local elimination of pathogen susceptible mosquitoes (e.g., malaria, dengue) while providing a barrier to prevent such reinvasion, but there are nuances to carefully consider for even this intervention. For example, population modification requires the spread of an evolutionary stable gene drive linked to an anti-pathogen effector with demonstrated stability and effectiveness against wild/evolving circulating pathogens. In 2015, a population modification approach was developed using a HGD linked to an antimalarial effector in Anopheles stephensi52, achieving super-Mendelian inheritance of the effector gene, however, both fitness costs and drive resistant alleles immediately appeared limiting the utility of this HGD. Recently, a recoded HGD rescue system in Anopheles stephensi was developed to relieve the fitness costs associated with a nonfunctional target site, and prevent the formation of resistance alleles, and this system showed promising performance in multi-generational laboratory population cages53 (Fig. 2G). This system could be further improved by redesigning the drive to target an essential gene and providing a recoded rescue within the drive. In fact, this architecture termed Home and Rescue (HomeR) has been recently demonstrated in flies with high transmission rates and low resistant allele generation rates, and robust performance in population cages54,55. Another study demonstrated an effector-linked HGD using minimal genetic modifications in malaria mosquitoes26 (Fig. 2H). Proof-of-principle experiments revealed that an effector construct containing homology arms to an endogenous gene and an artificial intron (gRNA and fluorescent marker) within the effector resulted in 99% of individuals inheriting the HGD. This study provides an exciting alternative approach towards designing HGDs with minimal components to decrease associated fitness costs and increase the drive efficiency of anti-pathogen effectors.
Additional nonhoming-based designs for modification include toxin-antidote CRISPR GD systems, such as “cleave and rescue” elements (ClvR)56,57 and “TARE” drives58, which can enhance their transmission by creating conditions in which progeny lacking these systems perish. These function using CRISPR to disrupt the function of an endogenous essential gene, and encode a linked cleavage-resistant copy of the target gene that can provide rescue to inheriting individuals. These nonhoming toxin-antidote GD designs are able to spread and overcome resistance-related challenges akin to homing-based drive architectures. Although ClvR has only been demonstrated as a proof-of-principle in fruit flies, this GD has the potential to become a promising strategy for future mosquito modification approaches.
To date, effectors have been engineered to overexpress endogenous transcription factors from innate immune pathways (i.e., Toll, IMD, and JAK-STAT), or to express synthetic effectors, such as single-chain antibodies, antiviral hammerhead ribozymes, and small RNAs that target mosquito-borne viruses via the host RNA interference (RNAi) pathway59,60. Many early iterations of these effectors, however, were limited in their ability to target multiple pathogens, or parts of the pathogen life cycle. Recently engineered strategies to address these critical issues have included multistage effector transgenes against different life stages of Plasmodium falciparum in A. stephensi61 (Fig. 2I), a dual-antiviral effector targeting two distinct viral families62 (Fig. 2J), and an anti-DENV effector against four genetically distinct DENV serotypes63 (Fig. 2K). Strategies against arboviruses such as ZIKV64 provide insights into how modification approaches could be adapted to re-emerging mosquito-borne pathogens (Fig. 2L). Notwitstanding these developments, while each of these effectors has been developed and rigorously tested in the laboratory, it remains to be determined how these will perform in complex ecosystems with variable environmental conditions when exposed to greater genetic diversity and diverse evolving microbial communities—will they be effective and for how long? Moreover, is it possible that these effectors could generate a bottleneck and thereby force the evolution of more virulent/pathogenic strains60? Given these concerns, significant future work needs to be undertaken to test their efficacy and stability when challenged with pathogens that are presently circulating and evolving in the environment60, prior to any release of such effectors linked to a GD into the environment.
Comparing Wolbachia and transgenic approaches
While at the forefront of innovation for mosquito-borne disease control, Wolbachia and transgenic approaches have distinct similarities and differences (Table 1). Particularly due to the extensive genetic toolbox currently available, transgenic-based approaches are flexible, optimizable, and permit designs of creative control approaches as compared to Wolbachia-based approaches which cannot be engineered. Transgenic approaches have been successfully applied to many mosquito species, whereas the success of Wolbachia transinfection and the stable transmission seems to be somewhat species-dependent (e.g., successful in Ae. aegypti and A. stephensi but difficult in An. gambiae). Gene editing tools also enable precise genetic changes that permit creative control approaches51. These tools can facilitate the development of GDs with varying degrees of spatiotemporal spread, persistence, and novel traits, although they are yet to be rigorously tested outside the lab20,65. In contrast, Wolbachia engineering has not been successful, thus Wolbachia-based methods depend on the inherent properties of the Wolbachia strains that are found in nature.
Optimization capabilities of pathogen resistance also vary by approach. Wolbachia strains are capable of blocking many arboviruses6,8,66, but they can do so only through mechanisms naturally dictated by the bacterium, which are not well understood, nor manipulatable. Transgenic approaches can be tailored to specific pathogens through various mechanisms (RNAi, immune pathways, etc.). This mechanistic aspect is an important design consideration, as it influences the ability to target pathogens at different developmental stages or multiple sites, which can be crucial for preventing or mitigating the emergence of pathogen resistance60,61. To date, there is no evidence of pathogen escape, or evasion, in Wolbachia-infected wild populations, but there have been numerous examples in laboratory studies67 with different pathogens and different arthropod hosts underscoring the importance of continued monitoring for such an escape. For example, an elegant artificial selection and gene association study on Wolbachia-infected mosquitoes collected from the WMP program release site in Cairns, Australia, was able to quickly select pathogen blocking phenotypes and identified 61 genes associated with modulation of pathogen blocking, suggesting that breakdown of pathogen blocking could occur easily under some circumstances68. If pathogen evasion did arise in wild populations, it may be difficult to modify this technology to address it or to remove the system from the environment.
Both approaches are likely to become established at a high frequency in relatively short time scales. Field releases of Wolbachia-infected mosquitoes have repeatedly demonstrated successful Wolbachia spread and effective pathogen blocking into populations on a scale ranging from 6 months to >2 years15,16,18,19,69. High temperatures may reduce CI and transmissibility of some Wolbachia strains though, which may impact their establishment and persistence in some field locations70. Theoretical modeling suggests that some HGD systems can be established in a population within a year of the initial release25,71. There is no current field data on HGDs, however, to validate these models.
The production and scaling cost considerations for these technologies may also differ. In general, the scaling costs are going to be lower for technologies that require lower release frequencies (Table 1). For these approaches, costs are generally going to be inversely related to persistence and confinability—the longer the system will persist and the farther it can spread—will generally result in lower production and scaling costs. Therefore, using Wolbachia for population modification will require less production and scaling costs than for Wolbachia IIT. For gene drive, non-confinable HGDs for either population modification, or suppression, would have less production and scaling costs than confineable split-HGDs which would require repeated releases to control a local population.
Some Wolbachia strains can block pathogen transmission, enabling release without sex-sorting, with the intent of Wolbachia-based population modification (i.e., using the selfish inheritance properties of Wolbachia). Notwithstanding, under certain laboratory conditions, Wolbachia strains have also been observed to enhance infections72,73,74, but it is not yet clear whether this phenomenon is applicable for stable Wolbachia infections released into the wild. In field demonstrations, however, Wolbachia was able to quickly invade wild populations and reduce pathogen transmission12,16,19. Given that evolution of either the virus, mosquito, or Wolbachia itself may result in alterations to the Wolbachia transmission blocking abilities—future efforts to characterize these long-term effects in wild populations where Wolbachia has been deployed should be of very high priority. Genetic control systems are intended to be transmitted only from parents to offspring (“vertical transmission”). The possibility of horizontal transmission to non-target species, followed by spread within that species, has been widely discussed but seems highly implausible.
Regulatory hurdles and public perception differ substantially between the two methods. Although mosquitoes transfected with Wolbachia are clearly modern biotechnological products, they have not encountered the same regulatory hurdles as transgenic approaches and go through different regulatory pathways75 (e.g., Wolbachia-based approaches are considered “veterinary chemical products” in Australia). This lack of regulatory clarity is an issue for genetically and non-genetically modified methods in many jurisdictions. Early engagement with communities, stakeholders, and the public has led to fewer public-relation barriers for Wolbachia-based approaches76. Both Wolbachia population suppression (IIT) and modification approaches have been successfully trialed in several countries. The same is true for transgenic suppression approaches; the RIDL approach successfully obtained regulatory and community approval in several countries, despite the more complex environment for genetically engineered organisms. Multiple trials in Brazil, Panama, and the Cayman Islands showed strong suppression of target Aedes mosquito populations. Some RIDL trials, however, have received strong public opposition, notably the trials in Key Haven, FL, which delayed trials in this area until recently77 while Wolbachia-based approaches have received essentially no opposition78. GD technologies have received significant opposition, but the lessons learned from GE have served GD programs, such as Target Malaria, and they have developed a meticulous, cautious step-wise phased approach towards a potential approval for transgenic GD releases. As transgene-based GD field releases have yet to become a reality, however, time will tell whether this seemingly more judicious approach to field trial approval meets expectations.
Finally, a remediation plan to recall these technologies is also essential. Both approaches have the possibility of losing function, for example, loss of transgene expression or pathogen evolving resistance to the linked effector60; or for Wolbachia loss of CI79, or reduction/loss of pathogen refractoriness which is vulnerable to environmental factors, temperature, and host diet80. Moreover, remediation may be necessary if these approaches are affected by an unintended consequence, shift in public opinion, or end of a trial period. Resistance alleles can limit transgene spread for GDs. However, innovative GD designs, such as reversal GDs that recall a problematic GD from the population20,81,82, have been proposed to address this problem46,83,84. Anti-CRISPR proteins can theoretically be applied as “natural brakes” to CRISPR-based HGDs85. Ongoing field studies indicate that Wolbachia can remain at high infection frequency with strong pathogen blocking and CI abilities for up to 8 years from initial invasion12. However, there is no simple way to remove Wolbachia-infected mosquitoes after release and spread. One could perhaps release mosquitoes infected with a different Wolbachia strain and exploit bidirectional incompatibilities between the two strains, replacing the old strain with the new one86. Alternatively, one could super-infect the old mosquito strain with an additional Wolbachia strain to generate a new strain that can spread into the already-invaded population. However, this scenario can lead to superinfection, where mosquitoes with multiple Wolbachia strains can have an incomplete maternal transmission or incompatible CI87. The release of wild-type mosquitoes to dilute the Wolbachia strain to sub-threshold levels is another potential remediation strategy; however, such wild-type releases would include large numbers of wild-type female mosquitoes capable of disease transmission and are therefore not ideal. Finally, IIT-SIT could be used to reduce the population below the threshold needed for persistence. If the populations are susceptible to insecticides, insecticide-based tools could also be used for remediation for some GD and Wolbachia technologies.
Concluding remarks and future perspectives
Wolbachia and transgene-based tools are both innovative approaches that may revolutionize mosquito-borne disease control. Immense progress has been made in genetically modified and Wolbachia-infected mosquitoes, leading to field trials around the world. Despite appreciable progress, knowledge gaps remain regarding Wolbachia-mosquito and Wolbachia-pathogen interactions. For example, not much is known about environment-host interactions, or how the host microbiome affects Wolbachia efficiency in mosquitoes74,88. Additional work is also needed to optimize CI and pathogen-blocking capabilities. Screening for temperature-insensitive Wolbachia strains is also crucial to avoid CI loss79. Identification and characterization of CI-inducing genes can pave the way for alternative control strategies. Likewise, additional work on transgene-based strategies is required, including reducing the cost of transgene fitness, finding ideal target sites for GD insertion, and eliminating resistance-allele formation, determining the effectiveness of anti-pathogen effectors using pathogens present in the field. For sterile male-based suppression approaches, male mosquitoes must be released multiple times. Improvements in mass mosquito production, precise sex separation, and release technologies are crucial to make these approaches more sustainable and cost-efficient3.
Ethical and regulatory issues over GD use, including the role of public participation in GD development89, informed consent, regulation90, possilbe use of global registries, and associated risks, should be carefully considered before any implementation91,92,93. Discussions regarding who should regulate and assess the risks of GD technology are in process and may take years to reach a consensus. The concept of a phased GD release approach is likely the best option to enable safe testing of the various components beginning with confinable approaches first. For example, to safely test GD components (e.g., CRISPR/Cas9) one could begin with a self-limiting type approach (e.g., pgSIT) to suppress the local population (Phase 1). This could be followed by a confinable split-GD approach which would enable the safe testing of linked effectors (Phase 2). Then if even necessary, this could be followed by a non-confinable GD approach—which would use the same components (e.g., gRNAs, Cas9, target genes, linked effectors, etc.) that were tested in the previous phases (Phase 3).
As Wolbachia-based population control technologies do not result in the genome modification of the target species, they do not have the notable stigma associated with genetic-based technologies. To date, Wolbachia-based control efforts have therefore been an easier technology for the public to accept. Several countries, including Australia, Malaysia, Indonesia, Vietnam, Colombia, and Brazil have already released Wolbachia-infected mosquitoes, with some observing reductions in local mosquito-borne disease transmission (Table 1). Regardless of the approaches used (whether transgenic or Wolbachia), scientists should scrutinize all proposed technologies to fully understand their advantages and disadvantages. There is no single silver bullet for mosquito disease control, and different communities may prefer different approaches that suit their local needs. Therefore, the development of multiple approaches is crucial.
Going forward, the prospect of controlling mosquito-borne diseases using innovative technologies is promising and we are in the golden age of the development of population control technologies. With increasing public confidence, time, and progress, we will continue to see these technologies developed and safely used to tackle global health issues and safe human lives.
Werren, J. H., Baldo, L. & Clark, M. E. Wolbachia: master manipulators of invertebrate biology. Nat. Rev. Microbiol. 6, 741–751 (2008).
Ng, L. C., Consortium, P. W.-S. et al. Wolbachia-mediated sterility suppresses Aedes aegypti populations in the urban tropics. medRxiv 2021.06.16.21257922 (2021) (first field comparison of Wolbachia IIT only and Wolbachia IIT and radiation-based SIT population control strategies in mosquitoes).
Crawford, J. E. et al. Efficient production of male Wolbachia-infected Aedes aegypti mosquitoes enables large-scale suppression of wild populations. Nat. Biotechnol. 38, 482–492 (2020).
Zheng, X. et al. Incompatible and sterile insect techniques combined eliminate mosquitoes. Nature 572, 56–61 (2019). First demonstration of field population reduction of a combined Wolbachia IIT and radiation-based SIT population control strategies in mosquitoes.
Moretti, R. & Calvitti, M. Issues with combining incompatible and sterile insect techniques. Nature 590, E1–E2 (2021). Commentary on Zheng et al. 2019 Nature paper highlighting potential issues associated with combining Wolbachia IIT and radiation-based SIT technologies.
Dutra, H. L. C. et al. Wolbachia blocks currently circulating Zika virus isolates in Brazilian Aedes aegypti mosquitoes. Cell Host Microbe 19, 771–774 (2016).
Flores, H. A. et al. Multiple Wolbachia strains provide comparative levels of protection against dengue virus infection in Aedes aegypti. PLoS Pathog. 16, e1008433 (2020).
Pereira, T. N., Rocha, M. N., Sucupira, P. H. F., Carvalho, F. D. & Moreira, L. A. Wolbachia significantly impacts the vector competence of Aedes aegypti for Mayaro virus. Sci. Rep. 8, 6889 (2018).
Geoghegan, V. et al. Perturbed cholesterol and vesicular trafficking associated with dengue blocking in Wolbachia-infected Aedes aegypti cells. Nat. Commun. 8, 526 (2017).
Bhattacharya, T., Newton, I. L. G. & Hardy, R. W. Viral RNA is a target for Wolbachia-mediated pathogen blocking. bioRxiv 2020.04.03.023556 (2020).
Lindsey, A. R. I., Bhattacharya, T., Newton, I. L. G. & Hardy, R. W. Conflict in the intracellular lives of endosymbionts and viruses: a mechanistic look at Wolbachia-mediated pathogen-blocking. Viruses 10, (2018).
Ryan, P. A. et al. Establishment of wMel Wolbachia in Aedes aegypti mosquitoes and reduction of local dengue transmission in Cairns and surrounding locations in northern Queensland. Aust. Gates Open Res. 3, 1547 (2019).
O’Neill, S. L. et al. Scaled deployment of Wolbachia to protect the community from dengue and other Aedes transmitted arboviruses. Gates Open Res. 2, 36 (2018).
Tantowijoyo, W. et al. Stable establishment of wMel Wolbachia in Aedes aegypti populations in Yogyakarta, Indonesia. PLoS Negl. Trop. Dis. 14, e0008157 (2020).
Indriani, C. et al. Reduced dengue incidence following deployments of Wolbachia-infected Aedes aegypti in Yogyakarta, Indonesia: a quasi-experimental trial using controlled interrupted time series analysis. Gates Open Res. 4, 50 (2020).
Utarini, A. et al. Efficacy of Wolbachia-infected mosquito deployments for the control of dengue. N. Engl. J. Med. 384, 2177–2186 (2021). A large scale field trial of a Wolbachia replacement strain, wMel, which demonstrated significant reduction in the incidence of symptomatic dengue and dengue associated hospitalizations.
Nazni, W. A. et al. Establishment of Wolbachia strain wAlbB in Malaysian Populations of Aedes aegypti for dengue control. Curr. Biol. 29, 4241–4248.e5 (2019).
Ahmad, N. A. et al. Wolbachia strain wAlbB maintains high density and dengue inhibition following introduction into a field population of Aedes aegypti. Philos. Trans. R. Soc. Lond. B Biol. Sci. 376, 20190809 (2021).
Pinto, S. B. et al. Effectiveness of Wolbachia-infected mosquito deployments in reducing the incidence of dengue and other Aedes-borne diseases in Niterói, Brazil: a quasi-experimental study. medRxiv 2021.01.31.21250726 (2021).
Champer, J., Buchman, A. & Akbari, O. S. Cheating evolution: engineering gene drives to manipulate the fate of wild populations. Nat. Rev. Genet. 17, 146–159 (2016).
Raban, R. R., Marshall, J. M. & Akbari, O. S. Progress towards engineering gene drives for population control. J. Exp. Biol. 223 (2020) (an updated review of the diversity of gene drives and their current state of development).
Friedman, R. M., Marshall, J. M. & Akbari, O. S. Gene drives new and improved. Issues Sci. Technol. XXXVI, 1–7 (2020).
Alphey, L. S., Crisanti, A., Randazzo, F. F. & Akbari, O. S. Opinion: Standardizing the definition of gene drive. Proc. Natl Acad. Sci. USA 117, 30864–30867 (2020).
Rasgon, J. L. Multi-locus assortment (MLA) for transgene dispersal and elimination in mosquito populations. PLoS ONE 4, e5833 (2009).
Li, M. et al. Development of a confinable gene drive system in the human disease vector Aedes aegypti. eLife 9, e51701 (2020). Seminal demonstration of a more spatially confineable, split-HGD in the dengue, yellow fever and Zika vector, Aedes aegypti.
Hoermann, A. et al. Converting endogenous genes of the malaria mosquito into simple non-autonomous gene drives for population replacement. bioRxiv 2020.05.09.086157 (2020).
Verkuijl, S. A. N. et al. A CRISPR endonuclease gene drive reveals two distinct mechanisms of inheritance bias. bioRxiv 2020.12.15.421271 (2021).
Galizi, R. et al. A synthetic sex ratio distortion system for the control of the human malaria mosquito. Nat. Commun. 5, 3977 (2014).
Galizi, R. et al. A CRISPR-Cas9 sex-ratio distortion system for genetic control. Sci. Rep. 6, 31139 (2016).
Buchman, A. B., Ivy, T., Marshall, J. M., Akbari, O. S. & Hay, B. A. Engineered reciprocal chromosome translocations drive high threshold, reversible population replacement in Drosophila. ACS Synth. Biol. 7, 1359–1370 (2018).
Akbari, O. S. et al. A synthetic gene drive system for local, reversible modification and suppression of insect populations. Curr. Biol. 23, 671–677 (2013).
Buchman, A. et al. Engineered reproductively isolated species drive reversible population replacement. Nat. Comm. 12, 3281 (2021).
Esvelt, K. M., Smidler, A. L., Catteruccia, F. & Church, G. M. Concerning RNA-guided gene drives for the alteration of wild populations. Elife 3, (2014) (landmark publication outlining in great depth how homing endonuclease gene drives could be developed using CRISPR-Cas9 technology).
Noble, C., Adlam, B., Church, G. M., Esvelt, K. M. & Nowak, M. A. Current CRISPR gene drive systems are likely to be highly invasive in wild populations. Elife 7, (2018).
DiCarlo, J. E., Chavez, A., Dietz, S. L., Esvelt, K. M. & Church, G. M. Safeguarding CRISPR-Cas9 gene drives in yeast. Nat. Biotechnol. 33, 1250–1255 (2015).
Akbari, O. S. et al. BIOSAFETY. Safeguarding gene drive experiments in the laboratory. Science 349, 927–929 (2015).
Kandul, N. P. et al. Assessment of a split homing based gene drive for efficient knockout of multiple genes. G3 10, 827–837 (2020).
Noble, C. et al. Daisy-chain gene drives for the alteration of local populations. Proc. Natl Acad. Sci. USA 116, 8275–8282 (2019).
Hammond, A. et al. A CRISPR-Cas9 gene drive system targeting female reproduction in the malaria mosquito vector Anopheles gambiae. Nat. Biotechnol. 34, 78–83 (2016). First demonstration of a gene drive for the suppression of mosquito populations.
Marinotti, O. et al. Development of a population suppression strain of the human malaria vector mosquito, Anopheles stephensi. Malar. J. 12, 142 (2013).
Windbichler, N. et al. A synthetic homing endonuclease-based gene drive system in the human malaria mosquito. Nature 473, 212–215 (2011).
Kyrou, K. et al. A CRISPR–Cas9 gene drive targeting doublesex causes complete population suppression in caged Anopheles gambiae mosquitoes. Nat. Biotechnol. 36, 1062–1066 (2018).
Simoni, A. et al. A male-biased sex-distorter gene drive for the human malaria vector Anopheles gambiae. Nat. Biotechnol. (2020) https://doi.org/10.1038/s41587-020-0508-1.
Hammond, A. M. et al. The creation and selection of mutations resistant to a gene drive over multiple generations in the malaria mosquito. PLoS Genet. 13, e1007039 (2017).
Unckless, R. L., Clark, A. G. & Messer, P. W. Evolution of resistance against CRISPR/Cas9 gene drive. Genetics 205, 827–841 (2017).
Marshall, J. M., Buchman, A., Sánchez, C. H. M. & Akbari, O. S. Overcoming evolved resistance to population-suppressing homing-based gene drives. Sci. Rep. 7, 3776 (2017).
Fu, G. et al. Female-specific flightless phenotype for mosquito control. Proc. Natl Acad. Sci. USA 107, 4550–4554 (2010).
Labbé, G. M. C., Scaife, S., Morgan, S. A., Curtis, Z. H. & Alphey, L. Female-specific flightless (fsRIDL) phenotype for control of Aedes albopictus. PLoS Negl. Trop. Dis. 6, e1724 (2012).
Kandul, N. P. et al. Transforming insect population control with precision guided sterile males with demonstration in flies. Nat. Commun. 10, 84 (2019).
Li, M. et al. Eliminating mosquitoes with precision guided sterile males. bioRxiv 2021.03.05.434167 (2021) (landmark demonstration of pgSIT for population suppression in a mosquito) (In press).
Li, M., Bui, M., Yang, T., White, B. J. & Akbari, O. S. Germline Cas9 expression yields highly efficient genome engineering in a major worldwide disease vector, Aedes aegypti. Proc. Natl Acad. Sci. USA 114, E10540–E10549 (2017).
Gantz, V. M. et al. Highly efficient Cas9-mediated gene drive for population modification of the malaria vector mosquito Anopheles stephensi. Proc. Natl Acad. Sci. USA 112, E6736–43 (2015).
Adolfi, A. et al. Efficient population modification gene-drive rescue system in the malaria mosquito Anopheles stephensi. Nat. Comm. 11, 5553 (2020).
Kandul, N. P., Liu, J., Bennett, J. B., Marshall, J. M. & Akbari, O. S. A confinable home-and-rescue gene drive for population modification. Elife 10, (2021).
Terradas, G. et al. Inherently confinable split-drive systems in Drosophila. Nat. Commun. 12, 1480 (2021).
Oberhofer, G., Ivy, T. & Hay, B. A. Cleave and rescue, a novel selfish genetic element and general strategy for gene drive. Proc. Natl Acad. Sci. USA 116, 6250–6259 (2019).
Oberhofer, G., Ivy, T. & Hay, B. A. Split versions of cleave and rescue selfish genetic elements for measured self limiting gene drive. PLoS Genet. 17, e1009385 (2021).
Champer, J. et al. A toxin-antidote CRISPR gene drive system for regional population modification. Nat. Commun. 11, 1082 (2020).
Reid, W. R., Olson, K. E. & Franz, A. W. E. Current effector and gene-drive developments to engineer arbovirus-resistant Aedes aegypti (Diptera: Culicidae) for a sustainable population replacement strategy in the field. J. Med. Entomol. (2021) https://doi.org/10.1093/jme/tjab030.
Marshall, J. M. et al. Winning the tug-of-war between effector gene design and pathogen evolution in vector population replacement strategies. Front. Genet. 10, 1072 (2019).
Dong, Y., Simões, M. L. & Dimopoulos, G. Versatile transgenic multistage effector-gene combinations for Plasmodium falciparum suppression in Anopheles. Sci. Adv. 6, eaay5898 (2020).
Yen, P.-S., James, A., Li, J.-C., Chen, C.-H. & Failloux, A.-B. Synthetic miRNAs induce dual arboviral-resistance phenotypes in the vector mosquito Aedes aegypti. Commun. Biol. 1, 11 (2018).
Buchman, A. et al. Broad dengue neutralization in mosquitoes expressing an engineered antibody. PLoS Pathog. 16, e1008103 (2020). First demonstration of a broad neutralizing antibody antiviral effector design and the first demonstration of an antiviral effector against all four dengue serotypes.
Buchman, A. et al. Engineered resistance to Zika virus in transgenic Aedes aegypti expressing a polycistronic cluster of synthetic small RNAs. Proc. Natl Acad. Sci. USA 116, 3656–3661 (2019).
Marshall, J. M. & Akbari, O. S. Can CRISPR-based gene drive be confined in the wild? A question for molecular and population biology. ACS Chem. Biol. 13, 424–430 (2018).
Fraser, J. E. et al. Novel Wolbachia-transinfected Aedes aegypti mosquitoes possess diverse fitness and vector competence phenotypes. PLoS Pathog. 13, e1006751 (2017).
Pimentel, A. C., Cesar, C. S., Martins, M. & Cogni, R. The antiviral effects of the symbiont bacteria Wolbachia in Insects. Front. Immunol. 11, 626329 (2020).
Ford, S. A. et al. Selection on Aedes aegypti alters Wolbachia-mediated dengue virus blocking and fitness. Nat. Microbiol 4, 1832–1839 (2019).
Aliota, M. T., Peinado, S. A., Velez, I. D. & Osorio, J. E. The wMel strain of Wolbachia reduces transmission of Zika virus by Aedes aegypti. Sci. Rep. 6, 28792 (2016).
Ross, P. A. et al. Wolbachia infections in Aedes aegypti differ markedly in their response to cyclical heat stress. PLoS Pathog. 13, e1006006 (2017).
Sánchez, C. H. M. et al. Modeling confinement and reversibility of threshold-dependent gene drive systems in spatially-explicit Aedes aegypti populations. BMC Biol. 18, 50 (2020).
Hughes, G. L., Vega-Rodriguez, J., Xue, P. & Rasgon, J. L. Wolbachia strain wAlbB enhances infection by the rodent malaria parasite Plasmodium berghei in Anopheles gambiae mosquitoes. Appl. Environ. Microbiol. 78, 1491–1495 (2012).
Amuzu, H. E. et al. Wolbachia enhances insect-specific flavivirus infection in Aedes aegypti mosquitoes. Ecol. Evol. 8, 5441–5454 (2018).
King, J. G., Souto-Maior, C., Sartori, L. M., Maciel-de-Freitas, R. & Gomes, M. G. M. Variation in Wolbachia effects on Aedes mosquitoes as a determinant of invasiveness and vectorial capacity. Nat. Commun. 9, 1483 (2018).
Chakradhar, S. Buzzkill: regulatory uncertainty plagues rollout of genetically modified mosquitoes. Nat. Med. 21, 416–418 (2015).
Dickens, B. L., Yang, J., Cook, A. R. & Carrasco, L. R. Time to empower release of insects carrying a dominant lethal and Wolbachia against Zika. Open Forum Infect. Dis. 3, ofw103 (2016).
Waltz, E. First genetically modified mosquitoes released in the United States. Nature 593, 175–176 (2021).
Bloss, C. S., Stoler, J., Brouwer, K. C., Bietz, M. & Cheung, C. Public response to a proposed field trial of genetically engineered mosquitoes in the United States. JAMA 318, 662–664 (2017).
Ross, P. A., Ritchie, S. A., Axford, J. K. & Hoffmann, A. A. Loss of cytoplasmic incompatibility in Wolbachia-infected Aedes aegypti under field conditions. PLoS Negl. Trop. Dis. 13, e0007357 (2019).
Yen, P.-S. & Failloux, A.-B. A review: Wolbachia-based population replacement for mosquito control shares common points with genetically modified control approaches. Pathogens 9, 404 (2020).
Vella, M. R., Gunning, C. E., Lloyd, A. L. & Gould, F. Evaluating strategies for reversing CRISPR-Cas9 gene drives. Sci. Rep. 7, 11038 (2017).
Wu, B., Luo, L. & Gao, X. J. Cas9-triggered chain ablation of cas9 as a gene drive brake. Nat. Biotechnol. 34, 137–138 (2016).
Champer, J. et al. Reducing resistance allele formation in CRISPR gene drive. Proc. Natl Acad. Sci. USA 115, 5522–5527 (2018).
Champer, S. E. et al. Computational and experimental performance of CRISPR homing gene drive strategies with multiplexed gRNAs. Sci. Adv. 6, eaaz0525 (2020).
Taxiarchi, C. et al. A genetically encoded anti-CRISPR protein constrains gene drive spread and prevents population suppression. Nat. Commun. 12 (2021).
Joubert, D. A. et al. Establishment of a Wolbachia superinfection in Aedes aegypti mosquitoes as a potential approach for future resistance management. PLoS Pathog. 12, e1005434 (2016).
Ant, T. H. & Sinkins, S. P. A Wolbachia triple-strain infection generates self-incompatibility in Aedes albopictus and transmission instability in Aedes aegypti. Parasit. Vectors 11, 295 (2018).
Hughes, G. L. et al. Native microbiome impedes vertical transmission of Wolbachia in Anopheles mosquitoes. Proc. Natl Acad. Sci. USA 111, 12498–12503 (2014).
Schairer, C. E., Triplett, C., Buchman, A., Akbari, O. S. & Bloss, C. S. Interdisciplinary development of a standardized introduction to gene drives for lay audiences. BMC Med. Res. Methodol. 20, 273 (2020).
Adelman, Z. et al. Rules of the road for insect gene drive research and testing. Nat. Biotechnol. 35, 716–718 (2017).
Callies, D. E. The ethical landscape of gene drive research. Bioethics 33, 1091–1097 (2019).
Schairer, C. E., Taitingfong, R., Akbari, O. S. & Bloss, C. S. A typology of community and stakeholder engagement based on documented examples in the field of novel vector control. PLoS Negl. Trop. Dis. 13, e0007863 (2019).
Long, K. C. et al. Core commitments for field trials of gene drive organisms. Science 370, 1417–1419 (2020).
Nguyen, T. H. et al. Field evaluation of the establishment potential of wMelPop Wolbachia in Australia and Vietnam for dengue control. Parasit. Vectors 8, 563 (2015).
Facchinelli, L. et al. Large-cage assessment of a transgenic sex-ratio distortion strain on populations of an African malaria vector. Parasit. Vectors 12, 70 (2019).
Carvalho, D. O. et al. Suppression of a field population of Aedes aegypti in Brazil by sustained release of transgenic male mosquitoes. PLoS Negl. Trop. Dis. 9, e0003864 (2015).
Harris, A. F. et al. Field performance of engineered male mosquitoes. Nat. Biotechnol. 29, 1034–1037 (2011).
Gorman, K. et al. Short-term suppression of Aedes aegypti using genetic control does not facilitate Aedes albopictus. Pest Manag. Sci. 72, 618–628 (2016).
This work was supported in part by funding from a Defense Advanced Research Project Agency (DARPA) Safe Genes Program Grant (HR0011-17-2-0047), and NIH awards (R21RAI149161A, R01AI151004, DP2AI152071) awarded to O.S.A. L.A. is supported by the UK Biotechnology and Biological Sciences Research Council (BBSRC) (BBS/E/I/00007033) and a DARPA PREEMPT award (HR001118S0017). J.L.R. is supported by NIH award R01AI116636 and NSF award 1645331. G.H.W. is supported by the Strategic Priority Research Program of the Chinese Academy of Sciences (Grant no. XDPB16).
O.S.A. is a founder of Agragene, Inc. and has an equity interest. The terms of this arrangement have been reviewed and approved by the University of California, San Diego in accordance with its conflict of interest policies. All other authors declare no competing interests.
Peer review information Nature Communications thanks the anonymous reviewer(s) for their contribution to the peer review of this work.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Wang, GH., Gamez, S., Raban, R.R. et al. Combating mosquito-borne diseases using genetic control technologies. Nat Commun 12, 4388 (2021). https://doi.org/10.1038/s41467-021-24654-z